WebSep 20, 2024 · This group of patients had locally advanced or metastatic disease and had not received prior systemic therapy. For the 147 people in the trial, objective response rate was 47.6%, which included some complete responses, and the disease control rate was 79.3% during a median follow up of 8.2 months. WebDec 17, 2024 · The primary end point is objective response rate, based on independent radiologic review (per RECIST v1.1); secondary objectives evaluated additional efficacy end points and safety. Results from PHAROS will describe the antitumor activity/safety of encorafenib plus binimetinib in patients with metastatic BRAF V600 -mutant NSCLC.
Sintilimab Plus Modified FOLFIRINOX in Metastatic or ... - Springer
WebNov 17, 2016 · The rate of confirmed objective response among all the patients who had been randomly assigned to the palbociclib–letrozole group was 42.1% (95% CI, 37.5 to 46.9), and among those in the ... WebApr 6, 2024 · Key Points. Question Does first-line nivolumab plus ipilimumab provide clinical benefit vs nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)?. Findings In this randomized clinical trial of 425 adults with platinum-refractory or platinum-eligible R/M SCCHN, the primary end point of objective … hill rom p8000 mattress
How long does Opdivo prolong life and what’s its success rate?
WebSecondary outcomes estimated using OR were disease objective response rate (DORR) and incidence of adverse events. Results: Four RCTs with a total of 3,013 patients researching the efficacy of immunotherapy plus chemotherapy versus chemotherapy alone on gastrointestinal cancer were included in this meta-analysis. WebSep 11, 2024 · Tumour response endpoints, such as overall response rate (ORR) and complete response (CR), are increasingly used in cancer trials. However, the validity of … WebSep 21, 2016 · Bruzzi et al 1 have evaluated objective response rate (ORR) as a potential surrogate end point for survival in metastatic breast cancer patients. Throughout oncology, many biomarkers have been evaluated. Examples include direct measures of the tumor burden process, such as ORR or progression-free survival (PFS), or inherently less … smart boost laundry additive